Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy.
about
ABO-compatible liver allograft antibody-mediated rejection: an update.Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: studies toward further defining their significance.Combined liver-kidney transplantation and the effect of preformed lymphocytotoxic antibodies.A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies.Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1Effect of donor age and sex on the outcome of liver transplantationThe adverse impact on liver transplantation of using positive cytotoxic crossmatch donorsIncreased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts.Preformed lymphocytotoxic antibodies: the effects of class, titer and specificity on liver vs. heart allografts.Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplantThe lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysisRetransplantation of liver: a comparison of FK 506- and cyclosporine-treated patients.Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features.The role of donor-specific HLA alloantibodies in liver transplantation.High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection Postliver transplant.Class II alloantibody and mortality in simultaneous liver-kidney transplantation.The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation.Antibody-mediated rejection as a contributor to previously unexplained early liver allograft lossLiver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model
P2860
Q33422561-F004287C-1E9B-470F-800C-AD43F4C7BF03Q33489591-9A34C624-D6D4-41EB-AE27-058B56B36FD2Q34205519-8F68FF06-E8C0-42D5-9C96-9831CA4EEE23Q34206939-8306A372-D9B8-4A4F-A9F2-1BD8453A8D58Q34247904-2BB80963-FB8E-4D9C-9E33-F1EE140923E5Q34248864-9D46476C-187E-4012-B385-00F0772BB91FQ34299410-4404725F-478C-4148-A74E-AC91812DF63AQ34304815-F0DB6769-2DAC-48C0-BB89-AB5C6C46C2DEQ34423424-D17473A5-96E3-4E24-8FCB-25AE7C9785B4Q34480437-73E9CD50-CCD7-4E13-89D3-3BDFD65928D3Q34858611-403798F7-3A23-4716-8A31-694EC6F2ADC9Q35160291-C2489C0F-5572-4A3D-B777-0591B4CAC2BAQ35546323-2D8CA274-06BF-4A98-8CF2-EBA209CA100DQ35547041-035E913E-A9FB-46A6-A889-CACED9B35130Q35547051-DF97B18A-0423-444A-BCB1-719103549DF2Q35547071-1680E4F9-5CC1-4859-8F57-99D48394DD10Q35975914-091995CD-38ED-4591-8568-487DB263B960Q36216606-7D0FBC5D-C955-4291-946C-AEBEAD367F39Q42094566-63383133-6925-4B10-997D-40180956FC28
P2860
Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy.
description
1991 nî lūn-bûn
@nan
1991 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Positive crossmatch in primary ...... yclosporine or FK 506 therapy.
@ast
Positive crossmatch in primary ...... yclosporine or FK 506 therapy.
@en
Positive crossmatch in primary ...... yclosporine or FK 506 therapy.
@nl
type
label
Positive crossmatch in primary ...... yclosporine or FK 506 therapy.
@ast
Positive crossmatch in primary ...... yclosporine or FK 506 therapy.
@en
Positive crossmatch in primary ...... yclosporine or FK 506 therapy.
@nl
prefLabel
Positive crossmatch in primary ...... yclosporine or FK 506 therapy.
@ast
Positive crossmatch in primary ...... yclosporine or FK 506 therapy.
@en
Positive crossmatch in primary ...... yclosporine or FK 506 therapy.
@nl
P2093
P2860
P1476
Positive crossmatch in primary ...... yclosporine or FK 506 therapy.
@en
P2093
P2860
P304
P407
P433
P577
1991-02-01T00:00:00Z